Tolerogenic insulin peptide therapy precipitates type 1 diabetes

Bergman, Marie-Louise; Lopes-Carvalho, Thiago; Martins, Ana-Catarina; Grieco, Fabio A.; Eizirik, Décio L.; Demengeot, Jocelyne

http://hdl.handle.net/10400.7/819

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
Demengeot_J.Exp.Med.(2017).pdf	main article	986.24 KB	Adobe PDF	Ver/Abrir
Demengeot_J.Exp.Med.(2017)_SM.pdf	supplementary materials	638.25 KB	Adobe PDF	Ver/Abrir

Contacte-nos

Autores

Bergman, Marie-Louise

Lopes-Carvalho, Thiago

Martins, Ana-Catarina

Grieco, Fabio A.

Eizirik, Décio L.

Demengeot, Jocelyne

Resumo(s)

Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease onset, increased its incidence, and worsened insulitis.

Descrição

This deposit is composed by the main article plus the supplementary materials of the publication.

Palavras-chave

Autoimmunity diabetes insulin Vaccination

URI

http://hdl.handle.net/10400.7/819

Citação

Tolerogenic insulin peptide therapy precipitates type 1 diabetes Marie-Louise Bergman, Thiago Lopes-Carvalho, Ana-Catarina Martins, Fabio A. Grieco, Décio L. Eizirik, Jocelyne Demengeot Journal of Experimental Medicine Jul 2017, 214 (7) 2153-2156; DOI: 10.1084/jem.20160471

Projetos de investigação

Novel immunotherapies for type 1 diabetes.

Projeto de investigaçãoVer mais

Editora

Rockefeller University Press

DOI

10.1084/jem.20160471

Coleções

LP - Letters

Licença CC

cclicense-by-nc-sa

Métricas Alternativas

Ver registo completo